Literature DB >> 11282173

Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts.

R Menéndez1, A M Amor, I Rodeiro, R M González, P C González, J L Alfonso, R Más.   

Abstract

BACKGROUND: Cholesterol biosynthesis is strictly controlled by 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase.
METHODS: Transfer of cultured fibroblasts to a lipid-depleted medium (LDM) up-regulates the enzyme levels. This, in turn, is followed by an accelerated biosynthesis of cholesterol.
RESULTS: Exposure of Vero fibroblasts to LDM and policosanol (0.5-50 microg/mL), a new cholesterol-lowering drug purified from sugarcane (Saccharum officinarum L.) wax, decreased in a dose-dependent manner cholesterol biosynthesis from [14C]-acetate and 3H-water, but not from [14C]-mevalonate.
CONCLUSIONS: This suggests an effect on HMG-CoA reductase, the rate-controlling enzyme in cholesterol biosynthesis. When enzyme activity was measured in the presence of various concentrations of policosanol (0.5-50 microg/mL), reductase was not suppressed. Therefore, there was no evidence for a competitive or noncompetitive inhibition of enzyme activity. However, after treatment of intact cells with policosanol (50 microg/mL) in the presence of LDM, a suppressive effect on enzyme activity was observed, suggesting a modulatory effect of policosanol on reductase activity. The previous inhibition of enzyme up-regulation by policosanol suggests to date a depression of de novo synthesis of HMG-CoA reductase and/or stimulation of its degradation. However, the exact mechanism by which policosanol inhibits the activity of HMG-CoA reductase still remains unclear. Further studies are needed to clarify the precise mechanism of its inhibitory action on cholesterol biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282173     DOI: 10.1016/s0188-4409(00)00265-4

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  20 in total

1.  Activation of AMP-kinase by policosanol requires peroxisomal metabolism.

Authors:  Subhashis Banerjee; Sarbani Ghoshal; Todd D Porter
Journal:  Lipids       Date:  2011-02-27       Impact factor: 1.880

2.  Policosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial.

Authors:  Barbara Swanson; Joyce K Keithley; Beverly E Sha; Louis Fogg; Judith Nerad; Richard M Novak; Oluwatoyin Adeyemi; Gregory T Spear
Journal:  Altern Ther Health Med       Date:  2011 Mar-Apr       Impact factor: 1.305

3.  Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy.

Authors:  James M Backes; Cheryl A Gibson; Janelle F Ruisinger; Patrick M Moriarty
Journal:  Lipids       Date:  2011-07-08       Impact factor: 1.880

4.  Effects of combination treatment with policosanol and omega-3 fatty acids on platelet aggregation: A randomized, double-blind clinical study.

Authors:  Gladys Castaño; Maria L Arruzazabala; Lilia Fernández; Rosa Mas; Daisy Carbajal; Vivian Molina; José Illnait; Sarahí Mendoza; Rafael Gámez; Melbis Mesa; Julio Fernández
Journal:  Curr Ther Res Clin Exp       Date:  2006-05

5.  Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters.

Authors:  Y W Wang; P J H Jones; I Pischel; C Fairow
Journal:  Lipids       Date:  2003-02       Impact factor: 1.880

6.  Policosanol as a new inhibitor candidate for vascular calcification in diabetic hyperlipidemic rats.

Authors:  Mohamed M Elseweidy; Nabila Zein; Samih E Aldhamy; Marwa M Elsawy; Saeid A Saeid
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-25

7.  Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol.

Authors:  Simonetta Oliaro-Bosso; Emanuela Calcio Gaudino; Stefano Mantegna; Enrico Giraudo; Claudia Meda; Franca Viola; Giancarlo Cravotto
Journal:  Lipids       Date:  2009-09-11       Impact factor: 1.880

8.  Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia.

Authors:  Marco Gentile; Ilenia Calcaterra; Alfonso Strazzullo; Carmen Pagano; Delia Pacioni; Enza Speranza; Paolo Rubba; Gennaro Marotta
Journal:  Clin Lipidol       Date:  2015-11-23

9.  Octacosanol administration to humans decreases neutral sterol and bile acid concentration in feces.

Authors:  Sylvia Keller; Franziska Gimmler; Gerhard Jahreis
Journal:  Lipids       Date:  2007-11-15       Impact factor: 1.880

Review 10.  Nutritional supplements and serum lipids: does anything work?

Authors:  Mary P McGowan; Suzanne Proulx
Journal:  Curr Atheroscler Rep       Date:  2009-11       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.